BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 2, 2010
View Archived Issues
Prometheus and AstraZeneca extend U.S. distribution agreement for Entocort EC
Read More
PI3K-delta inhibitor XL-499 shows promising preclinical activity
Read More
Somatic GNAQ/GNA11 mutations may contribute to development of uveal melanoma
Read More
Elara Pharma's new antitumor agent EL-102 inhibits HIF-1-alpha and cellular proliferation
Read More
PhaseBio begins phase I/IIa study of Glymera in type 2 diabetes
Read More
Phase II data presented on imatinib in diffuse cutaneous systemic sclerosis
Read More
Array to initiate clinical development of ARRY-382
Read More
Genzyme sells genetic testing business to LabCorp
Read More
Watson Pharma launches ella emergency contraceptive in U.S.
Read More
Health Canada approves velaglucerase alfa for type I Gaucher's disease
Read More
AxoGlia Therapeutics presents new inhibitors of Notch signaling pathway
Read More
Mymetics' HIV vaccine shows encouraging preliminary phase I results
Read More
Fresenius Medical Care and Galenica form new company
Read More
Pronova BioPharma describes new lipid molecules
Read More
Symphogen receives milestone payment for antibody therapeutic
Read More
NovaBay and FDA discuss clinical development of NVC-422 for impetigo
Read More
IRM discovers new prostaglandin E synthase inhibitors
Read More
Roche claims new isoquinoline derivatives
Read More
Roche divulges new inhibitors of beta-secretase 2
Read More
Phase I trial of INK-128 initiated in multiple myeloma
Read More
ImmunoGen begins phaseI/II trial of IMGN-901 for SCLC
Read More
Medivation and Astellas complete enrollment in phase III MDV-3100 trial
Read More
FDA to request further information for Cavatak IND for phase II melanoma trial
Read More
Janssen and GE Healthcare to codevelop diagnostic for Alzheimer's disease
Read More
Oncolytics Biotech begins enrollment in phase II Reolysin study in ovarian cancer
Read More
Study combines structural and functional tests to monitor progression of COPD
Read More